Endo International has acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings, a publicly-traded South African company that supplies branded and generic products in more than 150 countries. The transaction is expected to expand Endo’s presence in South Africa by adding a product portfolio that generated approximately $28 million last year as well as a sizeable pipeline of products in various phases of development that are expected to launch over the next several years.

This transaction underscores and helps to deliver upon Endo’s strategy of building its International Pharmaceuticals business unit through acquisitions. The company says its plan is to grow its International Pharmaceuticals business to represent 25% of its corporate revenues in the longer-term. The portfolio of products to be acquired from Aspen Holdings will be incorporated into Endo’s Litha Healthcare Group. Aspen Holdings will receive a one-time payment of approximately $130 million. Endo expects the transaction to close in third quarter 2015.

“With the acquisition of these products from Aspen Holdings, Endo continues to grow, diversify and optimize its international portfolio and, specifically, further expand its reach into hospital and pharmacy markets in South Africa,” said Rajiv De Silva, president and chief executive officer, Endo. “The transaction also continues to build Endo’s R&D pipeline and position the company for future organic growth with the addition of nearly 70 pipeline programs in development with multiple strengths and dosage forms across oncology, anti-infectives, cardiovascular and respiratory. We are excited about this opportunity as it furthers Endo’s corporate and M&A strategy.”